RSS Content

AtriCure Announces First Patient Enrollment in the DEEP IDE Trial Restart

The trial is intended to establish the safety and effectiveness of a dual epicardial and endocardial ablation procedure for patients with persistent or long-standing persistent atrial fibrillation

MASON, Ohio--(BUSINESS WIRE)--Apr. 23, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced the restart of the Dual Epicardial and Endocardial Procedure (DEEP) clinical trial (NCT02393885). Following approval by the FDA to restart the trial and enroll an additional 40 subjects, which was granted in December 2018, the first patient was treated by a team led by Professor Mark La Meir and Professor Carlo de Asmundis at Universitair Ziekenhuis Brussels, Belgium.

The DEEP trial is a prospective, multicenter, single arm, investigational device exempt (IDE) study to evaluate the safety and efficacy of the DEEP procedure in treating persistent and long-standing persistent atrial fibrillation. The DEEP procedure utilizes the specialized skills of both the cardiac surgeon and electrophysiologist (EP) for more severe cases of Afib, which have historically been the most difficult patients to treat. Up to 220 patients will be enrolled at up to 30 hospitals. Currently, 48 patients have been treated in the trial.

The global principal investigators for this trial are Dr. Kenneth Ellenbogen and Dr. Vigneshwar Kasirajan, from Virginia Commonwealth University, and Dr. Ali Khoynezhad, from Memorial Care Health & Vascular Institute at Long Beach, California.

“The DEEP trial brings electrophysiologists and cardiac surgeons together as a team in an effort to establish a safe and effective care pathway for patients presenting with persistent or long-standing persistent Afib. We are excited about the restart of enrollment in this important trial,” said Professor Mark La Meir, Professor of Cardiothoracic surgery at UZ Brussels who along with Professor de Asmundis treated the first patient upon restart.

“The DEEP trial reinforces AtriCure’s commitment to continue to expand the presence in minimally invasive treatment of persistent and long-standing persistent patients and to improve the lives of these difficult to treat patients,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “We’ve worked very closely with the FDA and with our investigators to do everything we can to ensure a safe, effective and repeatable procedure.”

About AtriCure, Inc.

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage (LAA) Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

Source: AtriCure, Inc.

Valerie Storch-Willhaus
Media Relations
Senior Director, Corporate Marketing and Communications
(612) 605-3311
vstorch-willhaus@AtriCure.com

Andy Wade
Investor Relations
Senior Vice President and Chief Financial Officer
(513) 755-4564
awade@AtriCure.com